UBS upgrades Snam on unjustified discount to peers, resilient growth outlook

UBS upgraded Italian gas utility Snam to buy from neutral, setting a €6.60 12-month target after the shares fell 10% over three months and reached an approximately 15% P/E discount to peers. UBS sees the discount as excessive given projected 2025-30 asset-base CAGR of 5.6%, normalized EPS CAGR of 4.1%, and dividend yield rising from 5.6% in 2026 to 6.5% by 2030. Key risks are the 2027 regulated WACC decision and 2028-31 regulatory review; under a harsher outcome, UBS estimates EPS could be 3%-4% below its base case.

Analysis

SRG is effectively a duration-sensitive regulated-asset trade rather than a pure gas-demand call. The key near-term valuation driver is the spread between Italian sovereign/utility yields and the allowed return set by ARERA: a benign 2027 WACC outcome can compress the current valuation discount quickly, while a modestly punitive ruling would validate a lower terminal multiple despite visible asset-base growth. The market is likely assigning a larger probability to post-2028 regulatory downside than the earnings sensitivity implied by current sell-side scenarios, creating an asymmetric setup only if rates stop rising.

The November WACC decision is the primary 1-3 month catalyst, but late-September parameter observations are the more important trading checkpoint because they determine whether higher market yields become embedded in the regulatory formula. The biomethane disposal is a secondary catalyst: proceeds near the upper end of market indications would support capital recycling and balance-sheet flexibility, but it should not be valued as incremental until price, tax leakage, and reinvestment use are disclosed. Hydrogen and CCS should receive little near-term credit; these projects are capital intensive and depend on tariff treatment, permitting, and customer contracting.

Contrarian risk is that SRG's apparent discount is not solely regulatory fear but a rational response to rising financing costs and a declining long-run gas-demand base. A 3-4% earnings downside under a relatively contained adverse regulatory case could still produce disproportionate equity downside if investors re-rate the stock as a lower-growth bond proxy. Thesis is falsified by a materially lower 2027 allowed return, tighter-than-expected opex assumptions in the next consultation, or Italian/European long-end yields resuming a sustained rise.

Key Decisions for Investors

• Watchlist SRG for a tactical long into the late-September WACC-parameter cutoff, rather than chase solely on the UBS upgrade. Enter only if Italian 10-year yields stabilize or decline and SRG remains materially below its regulated-utility peer valuation; target a 10-15% total-return move over 3-6 months, with risk control on a regulatory signal implying more than 3-4% EPS downside.
• Express the regulatory/rates thesis as long SRG versus short a broader Italian equity proxy (EWI) or European cyclicals, not an outright beta position. This isolates potential discount closure from Italian market risk; reassess immediately after the November WACC decision.
• Do not underwrite value from CCS/hydrogen optionality until SRG discloses regulated return treatment, capex commitments, and contracted utilization. Treat biomethane-sale proceeds as a catalyst watch item; a transaction below roughly €0.4bn or earmarking proceeds for low-return capex would weaken the bull case.
• Monitor ARERA consultation language on opex benchmarking and the 2027 WACC formula. A lower allowed return combined with no offset through inflation indexation or debt-cost recovery is a trigger to avoid/exit SRG, even if the dividend yield appears optically attractive.